Two-Time Stanley Cup Champion Shares Plans For Next Goal at NobleCon18


From the Blackhawks to the Biotech Industry, Daniel Carcillo Is On A Mission

The 18th annual conference will be “live” again! To celebrate the return to IN PERSON, thanks to our sponsors, investor registration is FREE

 

After seven recorded concussions as a result of his nine-year NHL career, Daniel Carcillo was left sleepless, plagued with migraines and at times suicidal. For years after leaving the ice, Carcillo relentlessly looked for solutions. For him and the millions who suffer from post-concussion syndrome, TBI and other mental health issues. In addition to creating a non-profit organization that assists former NHL-players with problems like his, Carcillo is the founder and CEO of Wesana Health, a life sciences company that leverages psilocybin-based medicine to treat traumatic brain injuries. Wesana recently announced that the FDA granted the Company’s request for a pre-IND (Investigational New Drug) meeting to discuss the novel therapy and proprietary protocol of SANA-013 for the treatment of Traumatic Brain Injury (TBI) related major depressive disorder (MDD).

Wesana is in the lineup of companies presenting at NobleCon18, and you can hear Daniel’s story as a panelist on the “Psychedelics: The Next Breakthrough in Mental Health Treatment?” Panel (Thursday, April 21, 8:00am).

ADMISSION IS FREE for institutional to self-directed novice investors, thanks to Noble, Channelchek, Sponsors and The Presenting Companies. Attendance is limited to 1,000.

NobleCon18 – Noble Capital Markets 18th Annual Small and Microcap Investor Conference – April 19-21, 2022 – Hard Rock, Hollywood, FL 100 Public Company Presentations | Scheduled Breakouts | Panel Presentations | High-Profile Keynotes | Educational Sessions | Receptions & Networking Events

REGISTER FREE AS AN INVESTOR  |  PRESENTING COMPANY INQUIRIES  |  NOBLECON INFO PAGE  |  NOBLECON18.COM  |  PRESENTING COMPANIES  |  SCHEDULED SPEAKERS

The Appeal of EVs with Bidirectional Charging


Image: SC Electric (Flickr)


Can My Electric Car Power My House? Not Yet for Most Drivers, but Vehicle-to-Home Charging is Coming

 

As manufacturers introduce new models of electric vehicles, demand for them is growing steadily. New EV sales in the U.S. roughly doubled in 2021 and could double again in 2022, from 600,000 to 1.2 million. Auto industry leaders expect that EVs could account for at least half of all new U.S. car sales by the end of the decade.

EVs appeal to different customers in different ways. Many buyers want to help protect the environment; others want to save money on gasoline or try out the latest, coolest technology.

In areas like California and Texas that have suffered large weather-related power failures in recent years, consumers are starting to consider EVs in a new way: as a potential electricity source when the lights go out. Ford has made backup power a selling point of its electric F-150 Lightning pickup truck, which is due to arrive in showrooms sometime in the spring of 2022. The company says the truck can fully power an average house for three days on a single charge.

So far, though, only a few vehicles can charge a house in this way, and it requires special equipment. Vehicle-to-home charging, or V2H, also poses challenges for utilities. Here are some of the key issues involved in bringing V2H to the mainstream.

Gasoline can flow only one way, from pump to car, but with some technical advances, EVs soon will be able to send power back to homes.

The ABCs of V2H

The biggest factors involved in using an EV to power a home are the size of the vehicles’ battery and whether it is set up for “bidirectional charging.” Vehicles with this capacity can use electricity to charge their batteries and can send electricity from a charged battery to a house.

There are two ways to judge how “big” a battery is. The first is the total amount of electric fuel stored in the battery. This is the most widely publicized number from EV manufacturers, because it determines how far the car can drive.

Batteries for electric sedans like the Tesla Model S or the Nissan Leaf might be able to store 80 to 100 kilowatt-hours of electric fuel. For reference, 1 kilowatt-hour is enough energy to power a typical refrigerator for five hours.

A typical U.S. home uses around 30 kilowatt-hours per day, depending on its size and which appliances people use. This means that a typical EV battery can store enough electric fuel to supply the total energy needs of a typical home for a couple of days.

The other way to assess the capacity of an EV battery is its maximum power output in backup power mode. This represents the largest amount of electric fuel that could be delivered to the grid or a house at any given moment. An EV operating in backup mode will typically have a lower maximum power output than when in driving mode. The backup power capacity is important, because it indicates how many appliances an EV battery could power at once.

This figure is not as widely publicized for all EVs, in part because vehicle-to-home charging hasn’t yet been widely deployed. Ford has advertised that its electric F-150 would have a maximum V2H power output of 2.4 kilowatts, potentially upgradable to 9.6 kilowatts – about the same as a single higher-end Tesla Powerwall home energy storage unit.

On the low end, 2.4 kilowatts is enough power to run eight to 10 refrigerators at the same time and could run much of a typical household continuously for a few days – or much more if the electricity is used sparingly. On the high end, a power level of 9.6 kilowatts could run more appliances or higher-powered ones, but that level of usage would drain the battery faster.

A person lies on the floor of a large meeting room, covered with fleece blankets

Storing power when it’s cheaper

To draw home power from their cars, EV owners need a bidirectional charger and an electric vehicle that is compatible with V2H. Bidirectional chargers are already commercially available, though some can add several thousand dollars to the price of the car.

A limited number of EVs on the market now are compatible with V2H, including the Ford Lightning, Nissan Leaf and Mitsubishi Outlander. General Motors and Pacific Gas & Electric plan to test V2H charging in California in mid-2022 using multiple GM electric vehicles.

Some homeowners might hope to use their vehicle for what utility planners call “peak shaving” – drawing household power from their EV during the day instead of relying on the grid, thus reducing their electricity purchases during peak demand hours. To do this, they might need to install special metering equipment that can control both the discharging of the vehicle battery and the flow of power from the grid to the home.

Peak shaving makes the most sense in areas where utilities have time-of-use electric pricing, which makes power from the grid much more expensive during the day than at night. A peak-shaving household would use cheap electricity at night to charge the EV battery and then store that electricity to use during the day, avoiding high electricity prices.

Siemens collaborated with Ford on custom bidirectional charger for F-150 Lightening


Utilities and the future of V2H

While V2H capabilities exist now, it will likely be a little while before they see widespread adoption. The market for V2H-compatible electric vehicles will need to grow, and the costs of V2H chargers and other equipment will need to come down. As with Tesla’s Powerwall, the biggest market for V2H will probably be homeowners who want backup power for when the grid fails but don’t want to invest in a special generator just for that purpose.

Enabling homeowners to use their vehicles as backup when the power goes down would reduce the social impacts of large-scale blackouts. It also would give utilities more time to restore service – especially when there is substantial damage to power poles and wires, as occurred during Hurricane Ida in Louisiana in August 2021.

Power companies will still have to spend money building and maintaining the grid to provide reliable service. In some areas, those grid maintenance costs are passed on to customers through peak demand charges, meaning that people without V2H – who will be more likely to have lower incomes – may well bear a greater share of those costs than those with V2H, who will avoid purchasing peak power from the grid. This is especially true if lots of EV owners use rooftop solar panels to charge their car batteries and use those vehicles for peak shaving.

Still, even with V2H, electric vehicles are a huge potential market for electric utilities. Bidirectional charging is also an integral part of a broader vision for a next-generation electric grid in which millions of EVs are constantly taking power from the grid and giving it back – a key element of an electrified future. First, though, energy planners will need to understand how their customers use V2H and how it may affect their strategies for keeping the grid reliable.

 

This article was republished with permission from The Conversation, a news site dedicated to sharing ideas from academic experts. It was written by and represents the research-based opinions of Seth Blumsack Professor of Energy and Mineral Engineering

 

Suggested Reading



How the Cost of Owning a New EV Could Also Climb Quickly



Enough US Produced Lithium to Exceed Today’s Demand





The Surprising Ways that Food Prices are Impacted by Oil Prices



Is the SEC conducting Unfounded Investigations of Elon Musk?

 

Stay up to date. Follow us:

 

The GEO Group, Inc. (GEO) – What Can End of Title 42 Mean?

Tuesday, April 05, 2022

The GEO Group, Inc. (GEO)
What Can End of Title 42 Mean?

With over 94,000 beds owned, leased or managed across its business lines and serving over 260,000 people daily, GEO is a leading provider of mission critical real estate to its governmental partners. The Company is the first fully integrated equity REIT specializing in the design, financing, development, and operation of secure facilities, processing centers, and community reentry centers in the U.S., Australia, South Africa, and the U.K.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Title 42 to End? The Biden Administration has stated the enforcement of Title 42 to expel immigrants will end May 23rd. First authorized in March 2020 during the COVID crisis, Title 42 continued to be enforced by the Biden Administration over the past year as a key tool to stop the spread of the virus in border facilities, but with the decline in COVID cases, the Administration will end the use of Title 42.

    Poised for a Surge? In the first five months of the government fiscal year, monthly Southwest border encounters are averaging nearly 170,000 and are on pace to top two million for the year.  Some reports suggest the number of people crossing once the restriction is lifted could triple to 18,000 per day, or more than double the current monthly encounter amount …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

CoreCivic, Inc. (CXW) – What Can End of Title 42 Mean?

Tuesday, April 05, 2022

CoreCivic, Inc. (CXW)
What Can End of Title 42 Mean?

CoreCivic is a diversified government solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that serve the public good through corrections and detention management, a growing network of residential reentry centers to help address America’s recidivism crisis, and government real estate solutions. We are a publicly traded real estate investment trust and the nation’s largest owner of partnership correctional, detention and residential reentry facilities. We also believe we are the largest private owner of real estate used by U.S. government agencies. The Company has been a flexible and dependable partner for government for more than 35 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Title 42 to End? The Biden Administration has stated the enforcement of Title 42 to expel immigrants will end May 23rd. First authorized in March 2020 during the COVID crisis, Title 42 continued to be enforced by the Biden Administration over the past year as a key tool to stop the spread of the virus in border facilities, but with the decline in COVID cases, the Administration will end the use of Title 42.

    Poised for a Surge? In the first five months of the government fiscal year, monthly Southwest border encounters are averaging nearly 170,000 and are on pace to top two million for the year.  Some reports suggest the number of people crossing once the restriction is lifted could triple to 18,000 per day, or more than double the current monthly encounter amount …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Metals & Mining First Quarter 2022 Review and Outlook

Monday, April 4, 2022

Metals & Mining Industry Report

Metals & Mining First Quarter 2022 Review and Outlook

Mark Reichman, Senior Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to end of report for Analyst Certification & Disclosures

  • Mining companies outperform broader market. During the first quarter, mining companies (as measured by the XME) appreciated 36.9% compared to a loss of 4.9% for the S&P 500 index. The VanEck Vectors Gold Miners (GDX) and Junior Gold Miners (GDXJ) ETFs were up 19.7% and 11.8%, respectively. Gold, silver, copper, and zinc futures prices rose 6.5%, 7.5%, 6.7%, and 20.9%, respectively, while lead was down 0.3%. The war in Ukraine has constrained supplies of commodities, everything from fertilizer, grain, oil, natural gas, and metals, and magnified inflationary trends. How long this will continue is uncertain.

  • Outlook for precious metals. The U.S. Dollar Index rose 2.4% during the first quarter, while the yield on a 10-year treasury note rose to 2.33% from 1.51% at year-end 2020. With the U.S. Federal Reserve signaling more aggressive action to combat inflation, further gains for gold may be challenged for the remainder of the year in the face of higher rates and a stronger dollar. However, with consumer and core inflation at 7.9% and 6.4% through February, respectively, real interest rates remain negative and enhance gold’s appeal as a store of value. Moreover, precious metals may be viewed as insurance against expected market volatility and economic uncertainty.

  • Risk of slowing economic growth may impact industrial metals. With the Federal Reserve behind the curve on inflation and an unanticipated war stressing commodity markets, choking back demand and growth may be an obvious choice to combat inflation and supply shortages. A key worry is the risk of recession in the U.S. and abroad versus a softer landing. However, improving supply chains, inventory re-stocking, and greater capital spending could be supportive of pricing, and we believe the long-term investment case for owning industrial metals mining companies remains favorable. However, industrial metals may also be challenged to post further gains into the latter part of the year.

  • Putting it all together. While much uncertainty remains, including the trajectory of the war in Ukraine, the U.S. Federal Reserve will likely achieve its goal of tamping down inflation. Despite a cautious near-term outlook, precious and industrial metals prices could hold up relatively well despite near-term headwinds. As a means of portfolio diversification, exposure to the mining sector is beneficial and investors may want to consider junior mining companies due to more attractive valuations relative to larger cap peers and the potential for increased M&A and industry consolidation.

GENERAL DISCLAIMERS

All statements or opinions contained herein that include the words “we”, “us”, or “our” are solely the responsibility of Noble Capital Markets, Inc.(“Noble”) and do not necessarily reflect statements or opinions expressed by any person or party affiliated with the company mentioned in this report. Any opinions expressed herein are subject to change without notice. All information provided herein is based on public and non-public information believed to be accurate and reliable, but is not necessarily complete and cannot be guaranteed. No judgment is hereby expressed or should be implied as to the suitability of any security described herein for any specific investor or any specific investment portfolio. The decision to undertake any investment regarding the security mentioned herein should be made by each reader of this publication based on its own appraisal of the implications and risks of such decision.

This publication is intended for information purposes only and shall not constitute an offer to buy/sell or the solicitation of an offer to buy/sell any security mentioned in this report, nor shall there be any sale of the security herein in any state or domicile in which said offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or domicile. This publication and all information, comments, statements or opinions contained or expressed herein are applicable only as of the date of this publication and subject to change without prior notice. Past performance is not indicative of future results. Noble accepts no liability for loss arising from the use of the material in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to Noble. This report is not to be relied upon as a substitute for the exercising of independent judgement. Noble may have published, and may in the future publish, other research reports that are inconsistent with, and reach different conclusions from, the information provided in this report. Noble is under no obligation to bring to the attention of any recipient of this report, any past or future reports. Investors should only consider this report as single factor in making an investment decision.


IMPORTANT DISCLOSURES

This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or discussed to another party, without the written consent of Noble Capital Markets, Inc. (“Noble”). Noble seeks to update its research as appropriate, but may be unable to do so based upon various regulatory constraints. Research reports are not published at regular intervals; publication times and dates are based upon the analyst’s judgement. Noble professionals including traders, salespeople and investment bankers may provide written or oral market commentary, or discuss trading strategies to Noble clients and the Noble proprietary trading desk that reflect opinions that are contrary to the opinions expressed in this research report.
The majority of companies that Noble follows are emerging growth companies. Securities in these companies involve a higher degree of risk and more volatility than the securities of more established companies. The securities discussed in Noble research reports may not be suitable for some investors and as such, investors must take extra care and make their own determination of the appropriateness of an investment based upon risk tolerance, investment objectives and financial status.

Company Specific Disclosures

The following disclosures relate to relationships between Noble and the company (the “Company”) covered by the Noble Research Division and referred to in this research report.
Noble is not a market maker in any of the companies mentioned in this report. Noble intends to seek compensation for investment banking services and non-investment banking services (securities and non-securities related) with any or all of the companies mentioned in this report within the next 3 months

ANALYST CREDENTIALS, PROFESSIONAL DESIGNATIONS, AND EXPERIENCE

Senior Equity Analyst focusing on Basic Materials & Mining. 20 years of experience in equity research. BA in Business Administration from Westminster College. MBA with a Finance concentration from the University of Missouri. MA in International Affairs from Washington University in St. Louis.
Named WSJ ‘Best on the Street’ Analyst and Forbes/StarMine’s “Best Brokerage Analyst.”
FINRA licenses 7, 24, 63, 87

WARNING

This report is intended to provide general securities advice, and does not purport to make any recommendation that any securities transaction is appropriate for any recipient particular investment objectives, financial situation or particular needs. Prior to making any investment decision, recipients should assess, or seek advice from their advisors, on whether any relevant part of this report is appropriate to their individual circumstances. If a recipient was referred to Noble Capital Markets, Inc. by an investment advisor, that advisor may receive a benefit in respect of
transactions effected on the recipients behalf, details of which will be available on request in regard to a transaction that involves a personalized securities recommendation. Additional risks associated with the security mentioned in this report that might impede achievement of the target can be found in its initial report issued by Noble Capital Markets, Inc. This report may not be reproduced, distributed or published for any purpose unless authorized by Noble Capital Markets, Inc.

RESEARCH ANALYST CERTIFICATION

Independence Of View
All views expressed in this report accurately reflect my personal views about the subject securities or issuers.

Receipt of Compensation
No part of my compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed in the public appearance and/or research report.

Ownership and Material Conflicts of Interest
Neither I nor anybody in my household has a financial interest in the securities of the subject company or any other company mentioned in this report.

NOBLE RATINGS DEFINITIONS
% OF SECURITIES COVERED
% IB CLIENTS
Outperform: potential return is >15% above the current price
94%
28%
Market Perform: potential return is -15% to 15% of the current price
6%
3%
Underperform: potential return is >15% below the current price
1%
0%

NOTE: On August 20, 2018, Noble Capital Markets, Inc. changed the terminology of its ratings (as shown above) from “Buy” to “Outperform”, from “Hold” to “Market Perform” and from “Sell” to “Underperform.” The percentage relationships, as compared to current price (definitions), have remained the same. Additional information is available upon request. Any recipient of this report that wishes further information regarding the subject company or the disclosure information mentioned herein, should contact Noble Capital Markets, Inc. by mail or phone.

Noble Capital Markets, Inc.
150 East Palmetto Park Rd, Suite 110
Boca Raton, FL 33432
561-994-1191

Noble Capital Markets, Inc. is a FINRA (Financial Industry Regulatory Authority) registered broker/dealer.
Noble Capital Markets, Inc. is an MSRB (Municipal Securities Rulemaking Board) registered broker/dealer.
Member – SIPC (Securities Investor Protection Corporation)

Report ID: 24663
Metals & Mining | April 4, 2022

GABY Inc. (GABLF) – GABY Inc. Focused on California Cannabis Consolidation

Monday, April 04, 2022

GABY Inc. (GABLF)
GABY Inc.: Focused on California Cannabis Consolidation

Gaby Inc is a wellness company that is engaged in the marketing of a variety of cannabis products, including flowers, concentrates, pre-rolls, edibles, topicals, tinctures, and other products. Some of its brands are Mankind, Sonoma Pacific, 2Rise, Lulu’s, and the Kind Republic. The company operates in two segments, namely licensed and unlicensed channels, both of which are in the manufacturing, distribution, and marketing of wellness products to address a variety of dietary and health concerns. All of its revenue comes from the United States.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Initiating Coverage. We are initiating research coverage on GABY Inc. GABY Inc. is a California-focused cannabis retail consolidator and the owner of San Diego-based Mankind Dispensary, one of the oldest and largest licensed dispensaries in the state. With significant organic and inorganic growth opportunities, we believe GABLF shares present an attractive risk/reward situation.

    Focus on California Consolidation.  GABY’s overarching strategy is to consolidate dispensaries in California. The Company’s first step was the April 2021 acquisition of Mankind Dispensary. The California market remains highly fragmented. No brand owns more than 2.5% of the retail dispensary locations and 4% of overall market share. Ripe for consolidation, in our view …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Blackboxstocks Inc. (BLBX) – Post Call Commentary and Updated Models

Monday, April 04, 2022

Blackboxstocks Inc. (BLBX)
Post Call Commentary and Updated Models

Blackboxstocks, Inc. is a financial technology and social media hybrid platform offering real-time proprietary analytics and news for stock and options traders of all levels. Our web-based software employs “predictive technology” enhanced by artificial intelligence to find volatility and unusual market activity that may result in the rapid change in the price of a stock or option. Blackbox continuously scans the NASDAQ, New York Stock Exchange, CBOE, and all other options markets, analyzing over 10,000 stocks and up to 1,500,000 options contracts multiple times per second. We provide our users with a fully interactive social media platform that is integrated into our dashboard, enabling our users to exchange information and ideas quickly and efficiently through a common network. We recently introduced a live audio/screenshare feature that allows our members to broadcast on their own channels to share trade strategies and market insight within the Blackbox community. Blackbox is a SaaS company with a growing base of users that spans 42 countries; current subscription fees are $99.97 per month or $959.00 annually. For more information, go to: www.blackboxstocks.com

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Subscribers Growing. Although management did not provide a current subscriber count, as management wants to see the stickiness of a recent marketing campaign before providing numbers, management did state the trajectory of subscriber growth is on track and they are pleased with subscriber growth. We expect management to update the subscriber level in the near future.

    Marketing Initiatives.  The Company continues to ramp up the marketing spend to attract new subscribers to the platform. The Company plans to run some TV ads this year, focused on CNBC, Fox Business, and, possibly, Bloomberg. We believe these ads will focus on targeting self directed investors …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Baudax Bio (BXRX) – Chairman Announces Resignation

Monday, April 04, 2022

Baudax Bio (BXRX)
Chairman Announces Resignation

Baudax Bio is a biopharmaceutical company focused on developing therapies for post-operative pain, peri-operative pain, and anesthesia. The company currently has one approved therapy in ANJESO for post-operative pain. Proprietary ANJESO (meloxicam) injection is the first and only once-daily IV analgesic. The company also has a pipeline of early-stage candidates with two novel neuromuscular blocking agents (NMBAs), a proprietary related reversal agent to their NMBAs, and Dex-IN, an intranasal formulation of dexmedetomidine (Dex) that has sedative, analgesic, and anti-anxiety properties.

Gregory Aurand, Senior Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Resignation announced.  Chairman of the Board of Directors Alfred Altomari announced March 30, 2022, that he was intending to resign. Mr. Altomari has been a director at Baudax Bio since 2019, and was a prior member of the Recro Pharma Board (Recro spun out Baudax Bio to shareholders in 2019). Mr. Altomari has extensive pharmaceutical experience and is currently Chairman and CEO at Agile Therapeutics, and serves on the board of Insmed, Inc.

    Resignation effective with shareholder meeting.  Mr. Altomari announced that his resignation would be immediately following the Annual Meeting of Shareholders to be held May 4, 2022 …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Filament Health (FLHLF) – FY2021 Reported With A Review Of Clinical Pipeline Progress

Monday, April 04, 2022

Filament Health (FLHLF)
FY2021 Reported With A Review Of Clinical Pipeline Progress

Filament Health Corp is a natural psychedelic drug discovery and extraction technology company. Its mission is to see safe, approved, natural psychedelics in the hands of everyone who needs them as soon as possible. Filament engages in natural extraction technology commercialization, utilizing its intellectual property portfolio, in-house GMP facility, and Health Canada psilocybin Dealer’s License.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Filament Made Substantial Progress During 4Q21.  Filament Health reported a full year loss of $9.3 million or $(0.06) per share. During the quarter, Filament advanced its clinical pipeline, made licensing agreements, and strengthened its intellectual property. The cash balance at December 31, 2021 was $4.6 million.

    Clinical Trials Have Begun.  During 4Q, Filament announced regulatory clearance for its first clinical trial. This trial began patient treatment in March 2022, testing its naturally-derived psilocybin and its bioactive form, psilocin. The trial has three arms to compare the standard doses of oral psilocybin (PEX010), oral psilocin (PEX020), and sublingual psilocin (PEX030) …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Ocugen (OCGN) – Gene Therapy Trial Reaches Progress Milestone

Monday, April 04, 2022

Ocugen (OCGN)
Gene Therapy Trial Reaches Progress Milestone

Ocugen Inc is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Ocugen Meets A Pipeline Milestone Ocugen announced treatment of the first patient in its Phase 1/2 trial for OCU400, the first product from its gene therapy platform to reach clinical trials.  OCU400 delivers genes to correct the genetic mutations that lead to retinitis pigmentosa, an ophthalmic condition that leads to vision loss and blindness. Patient screening began in 1Q22, meeting our expected timeframe for the trial. We see this milestone as good news for the product and the development pipeline.

    Phase 1/2 Trial Is Designed To Show Safety and Efficacy.  The OCU400 Phase 1/2 trial is designed with three cohorts at increasing dose levels. After establishing basic safety at the low dose, two additional cohorts will receive higher doses. The treatment delivers functional copies of the NR2E3 and RHO genes, regulatory genes that affect expression of other genes in the disease pathway. Preliminary …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Onconova Therapeutics (ONTX) – Narazaciclib Data Presented At Scientific Industry Conference

Monday, April 04, 2022

Onconova Therapeutics (ONTX)
Narazaciclib Data Presented At Scientific Industry Conference

Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Onconova Presented Data At The Next Generation Kinase Inhibitors Summit.  Onconova presented data from narazaciclib studies at an industry meeting attended by academic and corporate scientists. New data is not presented at this type of meeting, but speakers are able to present more information in greater detail than a medical meeting would typically allow. The communication with other scientists in the field also helps to establish a company’s expertise, and can lead to future collaborations, clinical site participation, and corporate partnerships.

    Data Gave An Overview and Summary of Narazaciclib.  Data was presented by Onconova’s Director of Corporate Development, and a session was chaired by Onconova’s CEO. These presentations gave data on narazaciclib’s activity against CDK4, CDK6, and other intermediaries in a pathway that leads to cancer cell growth, proliferation, and metastasis. The data showed potent inhibition consistent with the …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Fresh Vine Wine (VINE) Scheduled to Present at NobleCon18 Investor Conference


Fresh Vine Wine provides a preview of their upcoming presentation at NobleCon18

NobleCon18 – Noble Capital Markets 18th Annual Small and Microcap Investor Conference – April 19-21, 2022 – Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts | Panel Presentations | High-Profile Keynotes | Educational Sessions | Receptions & Networking Events

Free Registration Available – More Info


News and Advanced Market Data on VINE


NobleCon18 Presenting Companies

About Fresh Vine Wine

Fresh Vine Wine, Inc. (NYSE American: VINE) is a premier producer of lower carb, lower calorie premium wines in the United States, kicking off a 2022 growth plan following its IPO in mid-December 2021. Fresh Vine Wine’s brand vision is to lead the emerging natural and accessible premium wine category, as health trends continue to accelerate in the US marketplace. The 2020 US wine market was a $69 billion category. Fresh Vine Wine plans to accelerate growth in 2022 by amplifying its marketing, expanding product offerings, and expanding its team. Fresh Vine Wine positions its core brand lineup as an affordable luxury, retailing between $14.99-$22.99. Fresh Vine Wine’s varietals currently include its Cabernet Sauvignon, Chardonnay, Pinot Noir, and Rosé.

Eagle Bulk Shipping (EGLE) Scheduled to Present at NobleCon18 Investor Conference


Eagle Bulk Shipping provides a preview of their upcoming presentation at NobleCon18

NobleCon18 – Noble Capital Markets 18th Annual Small and Microcap Investor Conference – April 19-21, 2022 – Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts | Panel Presentations | High-Profile Keynotes | Educational Sessions | Receptions & Networking Events

Free Registration Available – More Info


Research News and Advanced Market Data on EGLE


NobleCon18 Presenting Companies

About Eagle Bulk Shipping

Eagle Bulk Shipping Inc. (“Eagle” or the “Company”) is a U.S.-based, fully integrated, shipowner-operator providing global transportation solutions to a diverse group of customers including miners, producers, traders, and end users. Headquartered in Stamford, Connecticut, with offices in Singapore and Copenhagen, Eagle focuses exclusively on the versatile mid-size drybulk vessel segment and owns one of the largest fleets of Supramax/Ultramax vessels in the world. The Company performs all management services in-house (including: strategic, commercial, operational, technical, and administrative) and employs an active management approach to fleet trading with the objective of optimizing revenue performance and maximizing earnings on a risk-managed basis. For further information, please visit our website: www.eagleships.com.